Related Experiment Video
Updated: Aug 18, 2025
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.5K
A framework for addressing Alzheimer's disease: Without a frame, the work has no aim
Daniel E Ball1, Soeren Mattke2, Lori Frank3
1Davos Alzheimer's Collaborative, Philadelphia, Pennsylvania, USA.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 8, 2022
Summary
This study introduces a flexible Alzheimer's disease (AD) systems preparedness framework to guide health systems in improving care for individuals with AD. The framework supports tailored solutions for better diagnosis, treatment, and support.
Area of Science:
- Gerontology
- Public Health
- Health Systems Management
Background:
- Alzheimer's disease (AD) care involves a complex network of patients, professionals, services, caregivers, and agencies.
- Transforming health systems to support individuals at risk for or diagnosed with AD presents significant challenges.
Purpose of the Study:
- To introduce a flexible Alzheimer's disease (AD) systems preparedness framework.
- To assist health systems in identifying opportunities for implementing and evaluating focused improvement programs for AD care.
Main Methods:
- Development of a flexible, adaptable framework for health systems.
- Inclusion of example metric concepts and initiatives across ten areas of focus.
- Provision of examples of funded projects for screening and early detection.
Main Results:
- The framework is designed for local adaptation across diverse health systems and countries.
- Health systems can tailor solutions to specific priorities within the framework's structure.
- Examples illustrate potential initiatives for screening and early detection.
Conclusions:
- The AD systems preparedness framework offers a structured approach for health system improvement.
- Stakeholders are encouraged to use the framework to generate and share implementation evidence.
- The ultimate goal is to enhance care and support for individuals with Alzheimer's disease.
More Related Videos
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.2K
Related Concept Videos
01:26Alzheimer's Disease: Overview
612
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
612
01:22Alzheimer's Disease: Treatment
240
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
240
01:30Dementia
153
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
153
01:15Parkinson's Disease: Overview
650
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
650
01:30Atherosclerosis I: Introduction
35
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
35
01:24Parkinson's Disease: Treatment
343
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
343